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RESEARCH ARTICLE
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Abstract
Molecular targeted therapies have been the focus of recent clinical trials for the treatment of
patients with recurrent epithelial ovarian cancer (EOC). The majority have not fared well as
monotherapies for improving survival of these patients. Poor bioavailability, lack of predic-
tive biomarkers, and the presence of multiple survival pathways can all diminish the suc-
cess of a targeted agent. Dasatinib is a tyrosine kinase inhibitor of the Src-family kinases
(SFK) and in preclinical studies shown to have substantial activity in EOC. However, when
evaluated in a phase 2 clinical trial for patients with recurrent or persistent EOC, it was
found to have minimal activity. We hypothesized that synthetic lethality screens performed
using a cogently designed siRNA library would identify second-site molecular targets that
could synergize with SFK inhibition and improve dasatinib efficacy. Using a systematic
approach, we performed primary siRNA screening using a library focused on 638 genes
corresponding to a network centered on EGFR, HER2, and the SFK-scaffolding proteins
BCAR1, NEDD9, and EFS to screen EOC cells in combination with dasatinib. We followed
up with validation studies including deconvolution screening, quantitative PCR to confirm
effective gene silencing, correlation of gene expression with dasatinib sensitivity, and
assessment of the clinical relevance of hits using TCGA ovarian cancer data. A refined list
of five candidates (CSNK2A1, DAG1,GRB2, PRKCE, and VAV1) was identified as showing
the greatest potential for improving sensitivity to dasatinib in EOC. Of these, CSNK2A1,
which codes for the catalytic alpha subunit of protein kinase CK2, was selected for addi-
tional evaluation. Synergistic activity of the clinically relevant inhibitor of CK2, CX-4945,
with dasatinib in reducing cell proliferation and increasing apoptosis was observed across
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multiple EOC cell lines. This overall approach to improving drug efficacy can be applied to
other targeted agents that have similarly shown poor clinical activity.
Introduction
Ovarian cancer is the second most common gynecological cancer afflicting women in the
United States [1]. With roughly 14,000 deaths and 22,000 new cases estimated annually, ovar-
ian cancer has the highest mortality-to-new case ratio among all gynecologic malignancies [1].
There are three main types of ovarian tumors classified based on their tissue of origin (surface
epithelium, stromal endocrine cells, and germ cells), with epithelial carcinomas accounting for
>90% of ovarian malignancies [2]. These epithelial tumors are generally further divided based
on their cellular morphology, the four most common subtypes being serous, endometrioid,
clear cell, and mucinous, with each subtype having different pathogenesis, chemo sensitivities,
and prognoses [2, 3]. Currently, the standard of care for women diagnosed with advanced
stage disease is optimal debulking surgery followed by taxane- and platinum-based chemother-
apy (generally paclitaxel or docetaxel in combination with carboplatin) [2]. Despite favorable
response rates to this initial treatment, ~75% of the patients eventually experience a recurrence
of a tumor that ultimately becomes treatment-resistant. Response to therapy is often less fre-
quent in patients with recurrent disease and of shorter duration compared to initial therapy.
Although improved in the last decade, the overall 5-year survival rate of patients with ovarian
cancer is still only 44% [1]. However, as additional molecular characterizations of disease sub-
types and a better understanding of their clinical biology and predictive biomarkers become
available, personalized medicine can be provided to improve patient outcomes through the
inclusion of targeted therapies [3–6].
Molecular targeted therapies are currently the major focus of clinical trials for the treatment
of patients with recurrent ovarian cancer [7–11]. The Src-family kinases (SFKs), the most
prominent member of the nine-member family being SRC kinase, are membrane associated
non-receptor tyrosine kinases frequently overexpressed and activated in a variety of human
cancers and cell lines [12], including a majority of late-stage serous, mucinous, and endome-
trioid epithelial ovarian tumors and EOC cell lines [13–16]. They play key roles in regulating
signal transduction from cell surface receptors [17–19] and therefore, modulate many cellular
functions including tumor progression and metastasis in a variety of human tumors and have
received a renewed interest as potential targets for therapy [20–23]. Dasatinib is an orally
administered ATP-competitive kinase inhibitor of the SFKs and the BCR-ABL fusion protein
as well as other tumor-relevant kinases [24, 25]. Dasatinib is one of three treatments available
to patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia
[26]. It continues to be investigated for anti-tumorigenic activity against a range of hematologic
and solid tumors (http://www.clinicaltrials.gov/). We recently reported the results of a Gyneco-
logic Oncology Group (GOG) sponsored Phase 2 clinical trial, GOG170M, evaluating dasatinib
for the treatment of patients with recurrent or persistent EOC or primary peritoneal carcinoma
[27]. Dasatinib showed minimal activity as a single agent in these patients [27], similar to the
results from many previous GOG-170 series of Phase 2 clinical trials evaluating other targeted
agents as monotherapies ([4], www.GOG.org).
In the vast majority of these single-agent trials, patient selection based on a particular bio-
marker was not done which may have improved the observed response rates. In addition, the
dysregulation and integration of multiple survival pathways in ovarian tumors [4] make single-
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agent therapies prone to succumb to theses activated networks. Therefore, in the current study,
our goal was to experimentally identify and validate second-site molecular target(s) that can
help sensitize ovarian cancer cells to dasatinib and thereby improve its efficacy. To achieve this
goal, we initially performed small interfering RNA (siRNA)-mediated gene silencing using a
library targeting protein networks relevant to ovarian cancer and SFK function. This library
was centered on receptor tyrosine kinases (RTKs) including epidermal growth factor receptor
(EGFR) and HER2; their effectors SHC1 and SHC3; and three CAS-family proteins, NEDD9,
BCAR1, and EFS, which directly bind and influence SFK and BCR-ABL, and in some cases
have been shown to influence dasatinib response [28–31]. We used this library to identify syn-
thetically lethal combinations that improve the sensitivity of EOC cells to dasatinib. We then
systematically narrowed our hit list from the primary screen and identified several candidate
dasatinib sensitizers (CSNK2A1, DAG1, GRB2, PRKCE, and VAV1). Of these, CSNK2A1 gener-
ated one of them more prominent sensitization effects in the siRNA screens and its expression
levels were found to be predictive of dasatinib sensitivity in a panel of EOC cell lines. In addi-
tion CSNK2A1 was overexpressed by almost 2-fold in patients with serous cystadenocarcino-
mas. Therefore, CSNK2A1 was deemed to be the most promising target among the five hits for
inhibition to enhance dasatinib activity. In vitro drug combination studies performed using
dasatinib and CX4945 (silmitasertib), the first and only clinically relevant CK2 inhibitor [32],
showed significant synergy across a panel of EOC cell lines in reducing proliferation and
increasing apoptosis. The focused, systematic approach that we have taken in this study to
identify second-site sensitizers to improve dasatinib efficacy can also be applied to other tar-
geted agents that have similarly shown poor clinical activity.
Results
Identification of dasatinib-sensitizing hits
The primary screening of an EOC cell line was performed using a custom designed, siRNA
library focused on targeting the signaling protein network centered on EGFR, HER2, SHC1,
SHC3, NEDD9, BCAR1, and EFS. This custom library consisted of 1,276 siRNA duplexes tar-
geting 638 human genes (a pool of two siRNAs per gene per well). The design and development
of this network-based focused siRNA screening library was previously described by Astsaturov
et al. [33]. We chose this library because it targeted many of the signaling proteins which act
upstream, downstream, or in parallel with SFK, given its interplay with RTKs [34, 35] and its
prominent role in facilitating signal transduction from RTKs [17–19], providing us with the
most relevant and likely candidates to target in combination with inhibition of SFK.
We used this focused library to screen an EOC cell line, A1847, derived from a patient with
an untreated, undifferentiated ovarian carcinoma [36, 37], to identify genes that provide resis-
tance to SFK inhibition via dasatinib treatment. This cell line was chosen because it provided
consistent, reproducible transfection data under high-throughput screening conditions in a
siRNA-based screen of the human druggable genome [38] and because it was sensitive to dasa-
tinib relative to other EOC cell lines (Pathak and Godwin, unpublished results). We hypothe-
sized that identification of second-site targets which further sensitize a sensitive cell line will
certainly provide some degree of sensitization to more resistant cell lines. Fig 1 provides a gen-
eral schematic of the overall experimental design (see the Materials and Methods section for
details of the screening). Following statistical analysis of the normalized cell viability data
obtained from the primary screening of the A1847 cells in the presence of siRNA + dasatinib
or siRNA + dimethyl sulfoxide (DMSO, the vehicle used to dissolve dasatinib), a sensitization
index (SI) value was calculated for each siRNA pool. A total of 84 genes with an SI value 0.85
Sensitizers to Dasatinib Therapy for Ovarian Cancer
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Fig 1. Overview of the design and work flow of experiments. A-F. A general schematic of the experimental workflow of the primary and secondary siRNA
screening and subsequent validation and refinement experiments performed to identify the second-site sensitizers for dasatinib. Details for each set of
experiments are provided in the subsequent Figures and Supplementary Figures and Tables throughout the Results section.
doi:10.1371/journal.pone.0144126.g001
Sensitizers to Dasatinib Therapy for Ovarian Cancer
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and a false discovery rate (FDR)< 10% representing ~13% of the genes targeted by this library
were selected for inclusion in the next round of screening (S1 Table, primary screen).
Eliminating false-positive hits
In order to eliminate potential false-positive hits from the initial screen that may be due to off-
target effects of the initially used siRNAs, we assembled a new library containing four individ-
ual siRNAs (1 siRNA/well) targeting each of the 84 genes identified in the primary screen.
With this new library of de-convoluted siRNAs, we performed a secondary screen in triplicate
and calculated the SI value for each siRNA as was done for the primary screen. S1 Fig shows
the correlation for 2 of the 3 screens for both the vehicle and dasatinib treatments. We consid-
ered genes as dasatinib-sensitizing only if they yielded an average SI value 0.85 for at least
two of the four individual siRNAs targeting a particular gene across the three biological repli-
cate experiments (S1 Table, secondary screen). Based on these more stringent criteria, we
removed 44 potential false-positive hits identified in the initial screen.
For the remaining 40 hits, we pooled the two best siRNAs targeting each gene (i.e. those
with the two lowest SI values identified from the secondary screens) and transfected the A1847
cells with this optimal pool of the two most effective siRNAs (2 siRNAs/well/gene) or the nega-
tive control siRNA, GL2, targeting the firefly-luciferase gene. Forty-eight hours following trans-
fection, we performed quantitative RT-PCR to determine mRNA levels in cells targeted by the
gene-specific siRNA pools relative to levels in cells targeted by the negative control siRNA. We
considered as being on-target only those siRNA pools that reduced gene expression by at least
70%. Based on these criteria for the qRT-PCR results, we narrowed our hit list of dasatinib-sen-
sitizing hits to 31 genes (S2 Table).
Specificity of dasatinib-sensitizing hits
Given that dasatinib inhibits other tyrosine kinases in addition to the SFKs, such as BCR-ABL, c-
KIT, and PDGFR [24], we next determined the level of specificity of the 31 hits for sensitizing
EOC cells to SFK inhibition. We used the pool of the two best siRNAs targeting each gene (identi-
fied from the de-convolution studies) and screened the 31 hits in combination with dasatinib or in
combination with another tyrosine kinase inhibitor, imatinib, which predominantly targets
BCR-ABL, PDGFR, and cKIT, with limited activity against the SFKs [39, 40]. siRNA-mediated
gene silencing in combination with imatinib resulted in only 2 of the 31 hits showing a sensitiza-
tion effect of 0.85, whereas all 31 siRNA pools generated SI values 0.85 when screened in
combination with dasatinib (S3 Table). The two hits identified from the imatinib combination
screen (GAB1 and JUP) were considered as being common sensitizers with dasatinib and therefore
were removed from additional studies, refining the dasatinib-specific hit list further to 29 hits.
Correlating gene expression to dasatinib sensitivity
In order to further delineate the second-site sensitizers to dasatinib, the basal level of gene
expression for the 29 dasatinib sensitizing hits was measured in seven EOC cell lines (A1847,
A2780, C30, CP70, OVCAR5, SKOV3, and UPN275) using 96☓96 dynamic arrays on the Bio-
Mark microfluidic quantitative PCR (qPCR) platform (Fluidigm) (Fig 2A). These EOC cell
lines were selected because they displayed varying levels of dasatinib sensitivity in previous
unpublished work by Pathak and Godwin. Therefore, we obtained a more precise measurement
of dasatinib sensitivity in these cell lines by measuring the dose response of each and calculat-
ing its viability at a dasatinib concentration of 1 μM (Fig 2B). The magnitude of correlation
(Spearman coefficient r) and statistical significance (p-value) were calculated for each gene in
order to identify potential genes whose expression levels correlated with dasatinib sensitivity
Sensitizers to Dasatinib Therapy for Ovarian Cancer
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(S3 Table). Four such genes (BCAR3, CSNK2A1, PRKCA, and PRKCE) were identified as being
predictive of dasatinib sensitivity, with a statistically significant correlation between expression
and drug sensitivity (p< 0.05, S3 Table and Fig 2C). Of these, CSNK2A1 and PRKCE are
inversely correlated with dasatinib sensitivity (i.e., low levels of these two genes result in higher
sensitivity to dasatinib) and therefore are potential secondary targets (e.g., drugs which reduce
their levels or activity in tumor cells would sensitize these cells to dasatinib).
Clinical relevance of dasatinib sensitizers
Genes whose protein products are aberrantly produced in excess in ovarian cancer patients can
potentially be targeted with inhibitors to reduce their activity. These proteins would be
Fig 2. Correlation of gene expression to dasatinib sensitivity. A. The basal level of gene expression of 29 dasatinib-sensitizing genes in seven EOC cell
lines was measured by using quantitative PCR performed with a 96☓96 dynamic array on the Fluidigm BioMark microfluidic platform. Shown is a
representative heat map of the dynamic array. Delta Ct values were calculated for each gene in each cell line (see Materials and Methods for details). B. Data
on the dose response to dasatinib for seven EOC cell lines were generated and cell viability at 1 μM dasatinib was calculated for each cell line as a
percentage of vehicle treated cells using GraphPad Prism. Shown is the average ± standard error of mean for each data point.C. Delta Ct and dasatinib
sensitivity data (i.e. viability at 1 μM drug concentration) were subjected to Spearman Correlation analysis using GraphPad Prism. The magnitude of
correlation (Spearman r value) is shown for the four genes which showed a statistically significant correlation (p < 0.05). Each point represents an EOC cell
line with the color matching the code shown in panel 2B. The line through the data points is for illustrative purposes only. S3 Table lists the r and p-values for
the other genes evaluated but which did not show significance.
doi:10.1371/journal.pone.0144126.g002
Sensitizers to Dasatinib Therapy for Ovarian Cancer
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considered clinically relevant therapeutic targets. Therefore, we analyzed gene expression data
available through the Cancer Genome Atlas (TCGA) data portal on ovarian cancer [41] for the
29 dasatinib-specific sensitizers listed in S3 Table. Gene expression data from 518 serous cysta-
denocarcinomas, the major histological subtype for EOC, and fallopian tube samples from 8
healthy individuals were obtained from the database. The fallopian tube epithelium has been
implicated as a source of origin for high grade serous ovarian cancer [42–45] and therefore an
appropriate comparison group. Of the 29 genes that were surveyed, an average increase in gene
expression levels greater than 1.5-fold in the tumor samples relative to the normal samples was
observed in five genes (CSNK2A1, DAG1, GRB2, VAV1, and YES1; Fig 3 and S4 Table). Inter-
estingly, two of these genes (CSNK2A1 and DAG1) were also among the top five hits with
respect to the level of sensitization to dasatinib observed when the genes were silenced (S3
Table).
In vitro drug combination of dasatinib and CX-4945
Given its over-expression in a majority of the ovarian tumor samples, its low SI value from the
screen, and its catalytic nature, CSNK2A1 is a top candidate for potential drug screening/devel-
opment and preclinical studies in combination with dasatinib. The CSNK2A1 gene codes for
the catalytic alpha subunit of protein kinase CK2, a serine-threonine kinase, and a CK2 inhibi-
tor, CX-4945 (silmitasertib) [46–48], has recently completed a phase 1 clinical trial as a poten-
tial anticancer drug [32]. It is the only ATP-competitive inhibitor against CK2 to have this
status. Therefore, we selected CX-4945 to study the effects on cell growth in a panel of estab-
lished EOC cell lines when combined with dasatinib. Cells were treated with each single agent
or a combination of the two drugs at a fixed molar ratio over a range of concentrations. Fig 4A
shows the dose-response curves for CX-4945 as a single agent (black line) and when combined
with dasatinib at a 20:1 molar ratio (gray dashed line). Dose response curves for two other
molar ratios evaluated (8:1 and 3:1) are shown in S2 Fig. Combination Index (CI) values were
calculated for each of the three ratios and are depicted in Fig 4B. Drug combinations which
Fig 3. Gene expression in clinical samples. Agilent gene expression data from TCGA on 518 serous cystadenocarcinomas and 8 fallopian tube samples
derived from healthy individuals were queried for 29 dasatinib sensitizing genes. The six Agilent probes that showed 1.5-fold increase in the average gene
expression of the respective genes in the tumor samples (gray boxes) relative to the controls (white boxes) are shown. The whiskers of each box plot
represent the expression values at the 5th and the 95th percentiles. The p-values were calculated using an unpaired two-tailed t-test using GraphPad Prism.
S4 Table lists the average expression values of the Agilent probes across the tumor and normal samples for all 29 genes.
doi:10.1371/journal.pone.0144126.g003
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result in Chou-Talalay CI values less than 1 are considered to be synergistic whereas combina-
tions which result in CI values greater than 1 are considered to be antagonistic [49, 50]. These
data suggest that the drugs are working synergistically to inhibit proliferation across the major-
ity of EOC cell lines.
We next evaluated the effects of the drug combination on cell cycle progression and cell
death using propidium iodide staining (S3 Fig). We did not detect any significant changes in
cell cycle phase distribution with either of the single agents at the doses used. However, the
combination treatment increased the percentage of sub-G1 cells in the majority of the cell
lines, suggesting the presence of cells undergoing apoptosis (Fig 5 and S3 Fig). We therefore
performed a direct measurement of apoptosis by measuring annexin V and cleavage of cas-
pase-3 and -7 (Fig 5). Both assays indicated increased levels of apoptosis in the combination
Fig 4. Drug combination using dasatinib and CX-4945. A. The Chou-Talalay method [78] was used to perform drug combination studies of dasatinib and
CX-4945. The points represent the average viability ± standard error of mean following 72 h of drug treatment at the indicated concentrations of CX-4945 (•)
and CX-4945 + dasatinib (◆; constant molar ratio of 20:1 of CX-4945:dasatinib) for the various EOC cell lines as a percentage of vehicle treated cells. The
curve-fit lines were generated using non-linear regression analysis in GraphPad Prism. Data for the other molar ratios that were evaluated are presented in
S2 Fig. B. The dose response data were used to calculate the Combination Index (CI) values for each cell line at the various molar ratios using CalcuSyn
software [79]. CI values less than 1 suggest that the drugs are working synergistically. Shown is the average calculated CI value ± standard error of the
mean.
doi:10.1371/journal.pone.0144126.g004
Sensitizers to Dasatinib Therapy for Ovarian Cancer
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treated cells relative to the other treatments. In many instances, the increase in the sub-G1 and
apoptotic cell population following combination treatment was greater than additive as indi-
cated by values larger than those calculated using the Bliss independence model [51].
Fig 5. Quantification of cell cycle and apoptosis assays.Cell cycle and apoptosis data were quantified for the indicated fold-changes relative to vehicle
treated cells and are presented as bar graphs showing the average fold-change ± standard error of mean. In all three assays, single (das, 0.5 μM; CX-4945,
10 μM) and combination drug treatments (das, 0.5 μM; CX4945, 10 μM) were for 72 h. P-values were calculated using a t-test comparing the combination
treatment group to each single agent treatment group. The dashed line indicates the theoretical value if the drugs act additively calculated using the Bliss
independence model (Bliss additivity value = FCDas + (FCCX-4945 * (100—FCDas))/100 where FC is fold-change [51]. Observed values larger than the Bliss
additivity value indicate synergy. See Materials and Methods for additional assay details.
doi:10.1371/journal.pone.0144126.g005
Sensitizers to Dasatinib Therapy for Ovarian Cancer
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Discussion
Dasatinib is an approved therapeutic for the treatment of several types of leukemia and is being
used worldwide in patients both newly diagnosed and those previously treated for these dis-
eases [26, 52–55]. It is also being investigated in early-stage clinical trials of other tumor types
(http://www.clinicaltrials.gov/, [56]). Although, as we have previously reported, it showed a
limited response as a single agent in previously treated patients with recurrent EOC [27], it is
nonetheless a potent inhibitor of the SRC family and BCR-ABL tyrosine kinases that is well tol-
erated by patients and for which our studies provide preclinical rationale to evaluate in combi-
nation with other targeted agents. In addition, inhibition of the SFKs has been suggested as a
mechanism to potentiate the anti-tumor activity of paclitaxel [57], the drug commonly used in
front-line therapy for patients with EOC. Identifying ways to improve dasatinib activity against
EOC would have significant and immediate clinical impact.
Towards this goal, we have taken a systematic, rational approach to identifying second-site
molecular targets which sensitize EOC cells to dasatinib. We have identified five genes
(CSNK2A1, DAG1, GRB2, PRKCE and VAV1) as candidate second-site sensitizers to dasatinib
and four genes (BCAR3, CSNK2A1, PRKCA, and PRKCE) as predictors of dasatinib sensitivity.
Although YES1 was identified as a potential second-site sensitizer (Fig 3 and S4 Table), we did
not consider it as a viable option for combination with dasatinib. This is because YES1 codes
for YES, a member of the SFK with a high degree of structural and functional homology with
other family members [58, 59]. In addition, dasatinib inhibits YES with the same selectivity as
other SFK members [24]. Therefore, we do not consider YES1 as a second-site molecular target
given that it appears dasatinib directly inhibits YES1 already. Of the remaining candidates,
CSNK2A1 is the top candidate for combination therapy based on the results presented in this
study. Its role in the biology of the cell and ovarian cancer and its interactions with SFK mem-
bers is briefly discussed below. A similar discussion is provided for the remaining hits as Sup-
porting Information.
CSNK2A1 codes for the catalytic alpha subunit of protein kinase CK2. This protein is a
ubiquitous, constitutively active serine/threonine kinase with essential roles in cell viability and
division, and in suppression of apoptosis [60–62]. CK2 is a promiscuous kinase, with over 300
potential substrates [63] and a dual role both in cell proliferation and death makes, that has
been implicated in many diseases [61]. CK2 protein levels are elevated in all cancers that have
been examined [62, 64]. TCGA data on ovarian cancer shows that the catalytic alpha subunit
of CK2 is overexpressed in a majority of ovarian tumors (Fig 3) and the MEK-MAPK-CK2
pathway has been implicated in phenotypic changes of a cell culture model representing pro-
gressive stages in the development of ovarian cancer [65]. CK2 has been identified as a promis-
ing therapeutic target for cancer therapy [62] and CX-4945, the clinical stage CK2 inhibitor
which has been evaluated in phase 1 trials, was shown to synergize with gemcitabine and plati-
num-based chemotherapeutics in vitro using ovarian cancer cell lines and in vivo using a
mouse xenograft model of ovarian cancer [51]. CK2’s relationship with the SFK members is
enigmatic with studies showing that CK2 can down-regulate the activity of at least three SFK
members (SRC, FYN, and YES) via direct phosphorylation of their threonine residues [66, 67]
while another study shows that tyrosine phosphorylation of CK2 by SFK members increases
CK2 catalytic activity [68]. How these two kinases interact with one another and whether this
is direct or through molecular chaperones such as CDC37 [69] or other signaling pathways
and how their activities are modulated is not entirely clear at the moment. Detailed mechanistic
studies are needed to provide a more thorough picture and to help generate a rationale for how
synergy between these two kinases may occur. Nevertheless, additional preclinical development
Sensitizers to Dasatinib Therapy for Ovarian Cancer
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using dasatinib and CX-4945 or other relevant inhibitors targeting SFK and CK2 for the treat-
ment of epithelial ovarian cancer are warranted.
Given the time and money invested and the most precious resources of all, the patients, into
developing safe, highly potent targeted drugs such as dasatinib and other similar molecularly
targeted agents, it is imperative that all potential avenues to improve these existing drugs be
evaluated. This includes identifying rational drug combinations, reformulation for alternate
routes of drug delivery, and repurposing for other diseases for which the drug was not initially
approved. Finally, identification of predictive biomarkers of response is essential for targeted
therapies in order to have greater precision in patient selection so that a true response rate is
measured for a given drug without being complicated by inclusion of patients who do not
respond simply because they were not suitable candidates to benefit from a particular drug. In
this study, we have taken a focused approach to identify several candidates for combination
therapy with dasatinib, a strategy that can be applied to other targeted agents that have simi-
larly shown poor clinical activity.
Materials and Methods
Cell culture
Epithelial ovarian cancer cell lines used in this study have been previously established or
derived by us under a protocol approved by the Fox Chase Cancer Center Institutional Review
Board and written informed consent (C30 and CP70 from parental A2780 cells [70]; UPN275
[38]). Cell lines established by other institutions were obtained as gifts from Dr. Thomas Ham-
ilton while at the Fox Chase Cancer Center (Philadelphia, PA) (A1847 and A2780 [36];
OVCAR5 [71]; SKOV3 [72]). All of the cell lines were maintained in normal growth media
consisting of RPMI 1640 media supplemented with fetal bovine serum (10% (vol/vol)), insulin
(7.5 μg/mL), penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37°C in a humidified
atmosphere with 5% CO2.
siRNA screening
Details on the design and assembly of the siRNA library used in the primary screen were previ-
ously described by Astsaturov et al. [33]. Briefly, the library was assembled using siRNAs from
Qiagen and consisted of eleven 96-well plates containing two siRNAs duplexes per well target-
ing a total of 638 genes arrayed into the inner 60 wells of each plate. The siRNA library used in
the secondary deconvolution screening was assembled using siRNAs from Qiagen and con-
sisted of four individual siRNA duplexes for each of the genes targeted in the deconvolution
screens arrayed one siRNA duplex per well into the inner 60 wells of 96-well plates. For both
the primary and secondary screens, positive control siRNAs targeting polo-like kinase 1
(PLK1) and negative control siRNAs targeting the firefly luciferase gene (GL2) were included
in quadruplicate on every plate. All siRNA transfections were done with a reverse transfection
method [73] using DharmaFECT-1 (Dharmacon) as the cationic lipid transfection reagent. For
the primary screen, DharmaFECT-1 was diluted in reduced-serum media (OptiMEM, Invitro-
gen) and added to the siRNAs arrayed in v-bottom 96-well dilution plates using a bulk reagent
microplate dispenser. The siRNA-lipid complexes were allowed to form for 30 min at room
temperature. Each siRNA-lipid complex was then aliquoted equally into four 96-well flat-bot-
tom test plates using a CyBio Vario liquid handler followed by addition of A1847 cells in nor-
mal growth media lacking antibiotics using a bulk reagent microplate dispenser (6,500 cells/
well,*95 μL final volume/well). The final DharmaFECT-1 dilution after cells were seeded was
1:700 and the final concentration of the siRNA duplex pools was ~50 nM (~25 nM of each
individual siRNA duplex). After 24 h, two of the four copies from each set of plates were treated
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with a sub-lethal dose of dasatinib (LC Labs; 5 μL/well, ~30 nM final, IC10-15) and the other
two copies were treated with an equal volume of the vehicle used to prepare the drug such that
the final DMSO concentration was the same (0.85% DMSO). Seventy-two hours following
drug addition, cell viability was determined by using CellTiter-Blue (CTB) (Promega). The
CTB reagent was diluted 3-fold in Ca2+/Mg2+-free Dulbecco’s phosphate buffered saline (PBS)
(1 part CTB + 2 parts PBS) prior to its addition to the assay plates (20 μL per well added using
a bulk reagent microplate dispenser). Fluorescence intensity (FI) was measured by using the
Envision (Perkin Elmer) multi-label microplate reader 3 h following addition of the CTB
reagent. Secondary deconvolution screens were performed using this same protocol with a
final siRNA concentration of 25 nM for the siRNA duplex in each well. When imatinib was
included in the screening procedure, a final concentration of 800 nM (IC10-15 for A1847 cells)
was used. FI data from all screens were analyzed as described below.
Statistical analysis for siRNA screens
To calculate cell viability following siRNA treatment, the FI value from each well targeted by
gene-specific siRNAs was divided by the mean FI value from four reference wells containing
the non-targeting negative control GL2 siRNA on each plate to yield a viability score (V)
defined as V = (fluorescence intensityspecific siRNA)/(mean fluorescence intensityGL2 siRNA)) cor-
responding to each gene. The sensitization index (SI) of each siRNA was then defined as the
viability of cells in the presence of siRNA and drug divided by the viability of the cells in the
presence of siRNA and vehicle (SI = (VsiRNA + drug)/(VsiRNA + vehicle)). All calculations were
automated using the cellHTS2 package [74] within the Bioconductor open source software
package (http://bioconductor.org) [75]. The effect of drug treatment on viability was measured
based on the normalized viabilities in the drug treated and vehicle wells using Limma [76].
Limma borrows strength across genes based on an empirical Bayes approach and identifies sta-
tistically significant changes in viability by combining information from a set of gene-specific
tests. Hits were identified based on statistical significance as well as biological significance. Sta-
tistical significance was determined by p-value controlled for the false discovery rate (FDR)
using the Benjamini-Hochberg method [77] to account for multiple testing. Hits showing an
FDR of less than 20% were considered statistically significant. Biological significance was arbi-
trarily defined as a decrease in the SI greater than 15%. Hits identified as statistically and bio-
logically significant were further validated.
Quantitative RT-PCR to measure gene knockdown
Forty-eight hours following transfection, total RNA was extracted from 4 replicate wells for
each siRNA pool using TRIzol reagent (Invitrogen). Each well was independently transfected
with the siRNA pool. The extracted RNA from the 4 wells was pooled and quantified using a
Nanodrop 1000 instrument (Thermo Scientific). Approximately 1 μg of the pooled total RNA
was reverse transcribed to cDNA in a 20 μL reaction containing 100 ng of random hexamers,
500 μmol/L of deoxynucleoside triphosphate mix, 10 mM dithiothreitol (DTT), 20 units of
M-MLV reverse transcriptase (SuperScript II), and 1☓ First Strand reverse transcription buffer
(all reagents for reverse transcription were from Invitrogen). Quantitative PCR (qPCR) reac-
tions (20 μL) were assembled in 384-well plates in triplicate wells consisting of 50 ng of cDNA,
1☓ TaqMan Gene Expression Assays (Applied Biosystems), and 1☓ TaqMan Universal PCR
Master Mix (Applied Biosystems). PCR product was detected in real time using an ABI7900
instrument (Applied Biosystems). Relative mRNA levels for each gene were assessed following
normalization to the internal reference control, cyclophilin A (PPIA) mRNA levels. The cycle
threshold (Ct) values were determined from the amplification curves for each sample and then
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normalized to the level of PPIA in that sample to calculate a ΔCt for each siRNA treated sample
as follows: ΔCtgene of interest or GL2 siRNA treated = Ctgene of interest or GL2 siRNA treated—CtPPIA. The
amount of mRNA remaining following siRNA treatment was calculated as follows: 2-ΔΔCt,
where ΔΔCt = ΔCtgene of interest siRNA treated - ΔCtGL2 siRNA treated. The percent of gene knock-
down following siRNA treatment was calculated as follows: (1-2-ΔΔCt)100.
Correlation of gene expression and drug sensitivity
The Fluidigm BioMark microfluidic qPCR platform was used to run 96☓96 dynamic arrays to
measure the basal mRNA expression levels in EOC cell lines grown as sub-confluent mono-
layer cultures. Total RNA from sub-confluent monolayer cultures was extracted using TRIzol,
quantified, and 200 ng of total RNA was reverse transcribed as described above. The resulting
cDNA for each sample was then pre-amplified using a multiplexed specific target amplification
protocol (Applied Biosystems) where each gene-specific TaqMan assay was pooled and used to
perform 14 cycles of a pre-amplification reaction with each gene-specific TaqMan assay at a
final concentration of 0.05x. The resulting pre-amplified cDNA was then diluted 5-fold and
used as the input cDNA for the subsequent qPCR using the 96☓96 dymanic arrays on the Bio-
Mark platform following manufacturer recommended protocols. For each cell line, two biolog-
ical replicate samples were obtained via two independent RNA extractions, reverse
transcription reactions, and qPCRs; six technical replicates for each biological replicate were
included on the dynamic arrays. The average ΔCt value from all biological and technical repli-
cates for each gene in each sample was calculated as described above using PPIA as the house-
keeping gene. The average ΔCt value for each gene from each EOC cell line and the cell
viability data of all seven EOC cell lines at 1 μM dasatinib (measured as described in the Sup-
plementary Information section) were subjected to Spearman Correlation using GraphPad
Prism to calculate the direction and magnitude of correlation (Spearman r value) and statistical
significance between the basal level of gene expression of a given gene and sensitivity to dasati-
nib across these cell lines.
Dasatinib drug sensitivity assays
After cell enumeration, EOC cell lines were seeded into 96-well plates (2 x 103 cells/well) using
normal growth media described above for the EOC cells. Twenty-four hours following seeding,
a 2.5-fold serial dilution of dasatinib was freshly prepared in DMSO/media and added to the
cells in triplicate wells maintaining a final DMSO concentration of 0.25% in all vehicle and
drug treated wells. Seventy-two hours following drug addition, 20 μL of diluted CTB was added
to each well to measure cell viability as described above. Two hours following CTB addition, FI
was measured by using an Infinite M200 PRO microplate reader (Tecan). Viability was defined
as a percentage of the ratio of FI values from drug treated wells to vehicle treated wells. Assays
were performed minimally as biological duplicates using triplicates wells within each experi-
ment. GraphPad Prism was used to fit the average values of the dose-response data to a four-
parameter equation (Y = bottom + (top—bottom)/(1+10(LogIC50—X)
HillSlope)). Cell viability at
1 μM dasatinib concentration was interpolated from the curve fit.
Drug combination assays
Drug combination studies were performed using the combination index (CI) method described
by Chou and Talalay [78]. Briefly, EOC cells were seeded into 96-well plates (2 x 103 cells/well)
as described above. Twenty-four hours after seeding, serial dilutions of either dasatinib, CX-
4945, or both dasatinib and CX-4945 were freshly prepared in DMSO/media and added to the
wells either as a single agent or as a combination such that the two drugs were always at a
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constant molar ratio in each serial dilution. Assays were performed as biological duplicates
using triplicate wells within each experiment. Cell viability following 72 h of treatment was
evaluated using CTB as described above and the viability data were then analyzed using Calcu-
Syn (ver 2.1, BioSoft, UK) [79] to calculate the synergy between the two drugs at each molar
ratio evaluated. Drug combinations which yielded CI values less than 1 were considered to be
synergistic [49, 50].
Cell cycle and apoptosis analysis
EOC cell lines were seeded in 6 cm dishes (2 x 105 cells/dish) and synchronized overnight in
the presence of 2 mM thymidine. Three hours after removal of the thymidine block, the cells
were treated with either vehicle (0.25% DMSO), dasatinib (0.5 μM), CX-4945 (10 μM), or the
combination of both drugs (das, 0.5 μM; CX4945, 10 μM). Seventy-two hours after treatment,
floating and adherent cells were collected by trypsin treatment. A portion of the cells were
immediately fixed using 70% ice-cold ethanol and stored overnight at -20°C before being used
for cell cycle analysis using propidium iodide staining (Guava Cell Cycle reagent, EMDMilli-
pore) following the manufacturer’s established protocol. The remaining cells were used to per-
form apoptosis analysis using the Guava Nexin reagent (EMDMillipore) which contains a
premixed cocktail of phycoerythrin-conjugated Annexin V and a cell impermeant dye
(7-AAD) following the manufacturer’s established protocol. The cell cycle assays were per-
formed three independent times with two technical replicates for each. The apoptosis assays
were performed four independent times with two technical replicates for each. A Guava Easy-
cyte HT instrument (EMDMillipore) was used to measure the changes in cell cycle and apo-
ptosis levels.
Caspase 3/7 measurement
EOC cells were seeded into 96-well plates (2 x 103 cells/well) as described above. Twenty-four
hours after seeding, cells were treated with vehicle (0.25% DMSO), dasatinib (0.5 μM), CX-
4945 (10 μM), or both drugs (das, 0.5 μM; CX4945, 10 μM). Following 72 h of treatment, cells
were subjected to Caspase-3 and -7 activity measurement using the Caspase-Glo 3/7 assay
(Promega) following the manufacturer’s protocol. Luminescence, which was directly propor-
tional to caspase activity, was measured using the Tecan Infinite M200 PRO microplate reader.
The caspase 3/7 measurements were performed two independent times with two technical rep-
licates for each.
Analysis of TCGA data
The log2 transformed Agilent gene expression values for the 29 genes of interest were down-
loaded from the ovarian cancer data portal supplied by TCGA (http://tcga-data.nci.nih.gov/
tcga/tcgaHome2.jsp) on 518 serous cystadenocarcinomas and 8 organ-specific healthy control
samples. Anti-log values were derived and the mean expression values for tumor samples and
control samples were calculated. The fold-change in the average expression in the tumors rela-
tive to the average expression in the controls was calculated and a Student’s two-tailed t-test
was performed to calculate a probability value, p. A fold-change of 1.5 with an associated p-
value< 0.05 was considered as a significant difference in expression between the tumor and
control samples.
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Supporting Information
S1 Fig. Correlation between replicate siRNA screens. Viability scores from two independent
biological replicate experiments evaluating 336 siRNAs from the secondary deconvolution
siRNA screens using A. siRNA + vehicle or B. siRNA + dasatinib were subjected to Spearman
Correlation analysis using GraphPad Prism. The magnitude of correlation (Spearman r value)
and the statistical significance of the correlation of the viability scores are shown. These 336
siRNAs are targeting the 84 genes (4 siRNA/gene; 1 siRNA/well) identified in the primary
screen (S1 Table).
(EPS)
S2 Fig. Combination of SFK and CK2 inhibitors at two additional molar ratios. The Chou-
Talalay method was used to perform drug combination studies of dasatinib and CX-4945. The
points represent the average viability ± standard error of mean following 72 h of drug treat-
ment at the indicated concentrations of CX-4945 (•) and CX-4945 + dasatinib (◆; constant
molar ratio of 20:1 of CX-4945:dasatinib) for the various EOC cell lines as a percentage of vehi-
cle treated cells. The curve-fit lines were generated using non-linear regression analysis in
GraphPad Prism. A. Shown are the data for a constant molar ratio of 8:1 of CX-4945:dasatinib
and B. 3:1 of CX-4945:dasatinib.
(EPS)
S3 Fig. Cell cycle phase distribution. EOC cell lines were treated with vehicle or the indicated
single agents (das, 0.5 μM; CX-4945, 10 μM) or combination of drugs (das, 0.5 μM + CX4945,
10 μM) for 72 h. Cells were harvested, ethanol-fixed, and analyzed by using propidium iodide.
Shown are representative histograms of the various phases of the cell cycle for the indicated
EOC cell lines following drug treatment. These data were used to calculate the percentage of
cells in the sub-G1 phase relative to vehicle treatment to generate the bar graphs in Fig 5.
(EPS)
S1 Table. Primary Screen – 84 genes out of 638 targeted genes were selected as "hits" follow-
ing the primary screen using pooled siRNAs (2 per well). Secondary Screen–Forty hits were
validated following secondary screening using individual siRNAs (1 per well; 4 per gene). The
two siRNAs identified as being optimal for each gene are indicated and were selected for use in
additional studies.
(PDF)
S2 Table. The percent reduction in gene expression following siRNA treatment using a
pool of the two optimal siRNAs per gene identified from the secondary deconvolution
screens is shown. The 31 genes selected for additional studies are indicated.
(PDF)
S3 Table. Specificity of hits – Sensitization index values were calculated following treat-
ment with dasatinib or imatinib. The two genes highlighted in yellow appear to synergize
with both drugs (SI 0.85) and therefore we did not use them for further studies. The remain-
ing 29 hits were considered as dasatinib-specific sensitizers. Correlation of hits–The Spearman
coefficient (r) and statistical significance (two-tailed t-test) for 29 genes were calculated using
GraphPad Prism to determine the correlation of gene expression with dasatinib sensitivity.
Genes highlighted in green show statistically significant correlation of basal gene expression
with dasatinib sensitivity. ND, not determined.
(PDF)
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S4 Table. An analysis of ovarian TCGA Agilent gene expression data of the 29 dasatinib
sensitizing hits in 518 serous cystadenocarcinomas and 8 fallopian tube samples derived
from healthy individuals was performed. Shown are the hits ranked by the average fold-
change in gene expression in the tumor samples relative to the control tissue. Data from multi-
ple probes are shown when available.
(PDF)
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